Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents

被引:92
作者
Sader, HS
Jones, RN
Stilwell, MG
Dowzicky, MJ
Fritsche, TR [1 ]
机构
[1] JMI Labs, N Liberty, IA 52317 USA
[2] Tufts Univ, Sch Med, Boston, MA 02111 USA
[3] Wyeth Pharmaceut, Collegeville, PA 19426 USA
关键词
bloodstream infection; tigecycline; Staphylococcus aureus; nosocomial infection;
D O I
10.1016/j.diagmicrobio.2005.05.005
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The activity of tigecycline (formerly GAR936), a novel glycylcycline, was tested against recent bloodstream infection (BSI) pathogen isolates from 6 continents. Frequency of clinical occurrence of these pathogens was determined and their antibiograms assessed using reference broth microdilution methods. A total of 26474 strains were tested for tigecycline susceptibility according to the Clinical and Laboratory Standards Institute (formerly the National Committee for Clinical Laboratory Standards) by the M7-A6 guidelines with interpretations from M100-S15 and the package insert. The rank order of pathogens was Staphylococcus aureus (33.1%), Escherichia coli (14.0%), coagulase-negative staphylococci (13.5%), Enterococeits spp. (12.3%), Klebsiella spp. (5.7%), Pseudomonas aeruginosa (4.2%), Enterobacter spp. (3.0%), beta-hemolytic streptococci (2.9%), Streptococcus pneumoniae (2.3%), and viridaris group streptococci (1.4%). Tigecycline exhibited a broader spectrum of activity against BSI isolates when compared to ciprofloxacin, tetracycline, aminoglycosides, and many beta-lactams (imipenem). Tigecycline was highly active against most pathogens tested, including staphylococci (MIC90, 0.5 mu g/mL), enterococci (MIC90, 0.25 mu g/mL), streptococci (MIC90, <= 0.12 mu g/mL), Escheriehia coli (MIC90, 0.25 mu g/mL), Klebsiella spp. (MIC90, 1 mu g/ mL), and Enterobacter spp. (MIC90, 2 mu g/mL), but showed limited inhibition of Pseudomonas aeruginosa (MIC90, 16 mu g/mL) and indolepositive or indole-negative Proteae (MIC90, 4-8 mu g/mL). In summary, tigecycline exhibited a wide spectrum of antimicrobial potency versus BSI isolates collected worldwide. Serious infections in nosocomial environments should benefit from tigecycline use among the investigational phase 3 agents focused toward resistant strains. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:181 / 186
页数:6
相关论文
共 19 条
[1]   Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA [J].
Bauer, G ;
Berens, C ;
Projan, SJ ;
Hillen, W .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (04) :592-599
[2]   In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum β-lactamases [J].
Biedenbach, DJ ;
Beach, ML ;
Jones, RN .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2001, 40 (04) :173-177
[3]   Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002) [J].
Biedenbach, DJ ;
Moet, GJ ;
Jones, RN .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2004, 50 (01) :59-69
[4]  
Bradford P. A., 2004, Clinical Microbiology Newsletter, V26, P163, DOI 10.1016/j.clinmicnews.2004.10.001
[5]  
*CLIN LAB STAND I, 2005, 15 INF S M100 S15
[6]   In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and Gram-positive cutaneous infections [J].
Fritsche, TR ;
Kirby, JT ;
Jones, RN .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2004, 49 (03) :201-209
[7]   Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections [J].
Fritsche, TR ;
Jones, RN .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 24 (06) :567-571
[8]   Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates [J].
Gales, AC ;
Jones, RN .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2000, 36 (01) :19-36
[9]   The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting [J].
Ibrahim, EH ;
Sherman, G ;
Ward, S ;
Fraser, VJ ;
Kollef, MH .
CHEST, 2000, 118 (01) :146-155
[10]   Disk diffusion susceptibility test development for the new glycylcycline, GAR-936 [J].
Jones, RN .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1999, 35 (03) :249-252